Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial

Journal of Infectious Diseases

Volumn 209, Issue 12, 2014, Pages 1916-1920

  Wei, Xierong ^a   Hunt, Gillian ^d   Karim, Salim S Abdool ^b,f   Naranbhai, Vivek ^f   Sibeko, Sengeziwe ^f   Karim, Quarraisha Abdool ^b,f   Li, Jin Fen ^a   Kashuba, Angela D M ^c   Werner, Lise ^f   Passmore, Jo Ann S ^e,f   Morris, Lynn ^d   Heneine, Walid ^a   Johnson, Jeffrey A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d National Institute for Communicable Diseases   (United States)

^e NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

HIV prevention; pre exposure prophylaxis; tenofovir gel; topical PrEP; Vaginal microbicide

Indexed keywords

PLACEBO; TENOFOVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SMEAR; CONTROLLED STUDY; DRUG TISSUE LEVEL; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING; SENSITIVITY ANALYSIS; SEROCONVERSION; VAGINA SMEAR; VIRUS TRANSMISSION;

HIV PREVENTION; PRE-EXPOSURE PROPHYLAXIS; TENOFOVIR GEL; TOPICAL PREP; VAGINAL MICROBICIDE;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GELS; HIV INFECTIONS; HIV-1; HUMANS; ORGANOPHOSPHONATES; POLYMERASE CHAIN REACTION; SOUTH AFRICA; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; VIRAL LOAD; YOUNG ADULT;

EID: 84901788182     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu026     Document Type: Article

References (10)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.
2. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
3. Johnson JA, Li J-F, Wei X, et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE 2007; 2:e638.
4. Li JF, Lipscomb JT, Wei X, et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis 2011; 203:798-802.
5. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24:1203-12.
6. Chan PA, Huang A, Kantor R. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis. J Int AIDS Soc 2012; 15:17701-6.
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
8. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
9. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
10. Dobard C, Sharma S, Martin A, et al. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 2012; 86:718-25.